基于贝拉塔塞普特的免疫抑制:什么以及何时结合?
Juliana Schilsky1, Reut Hod Dvorai2, Christine Yang3
1Norton College of Medicine, SUNY Upstate Medical University, Syracuse, NY, USA.
Transplant immunology
|May 29, 2024
概括
基于贝拉塔塞普的救援方案显示了可比的移植结果,包括稳定的EGFR和移植存活率. 这些发现支持贝拉 (Bela) 在移植患者的各种免疫抑制组合中的安全性和有效性.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 免疫抑制是一种免疫抑制.
- 移植医学 移植医学 移植医学
背景情况:
- 接受脏移植的人通常需要救援免疫抑制疗法.
- 贝拉塔塞普是维持免疫抑制的一个选择.
- 评估基于贝拉塔塞普的救援方案对于优化移植结果至关重要.
研究的目的:
- 为了检查基于贝拉塔塞普的救援免疫抑制对移植结果的影响.
- 为了比较不同基于belatacept的救援方案的结果.
- 评估belatacept在救援治疗中的安全性和有效性.
主要方法:
- 成年移植受体 (2011-2022) 的单中心回顾性研究.
- 被转换为贝拉塔塞普特救援疗法的患者.
- 收集的数据包括eGFR,移植存活率,感染/新发生率,组织学和捐赠者特异性抗体 (DSA).
主要成果:
- 三组:货币货币基金/贝拉 (n=28),CNI/贝拉 (n=22),CNI/货币货币基金/贝拉 (n=13).
- 贝拉塔塞普后的DSA下降了 (15.67%,p=0.15). 在使用贝拉塔塞普后的DSA下降了 (15.67%,p=0.15).
- 两组之间在eGFR,移植存活率或死亡/异构移植失败的发生率上没有显著差异.
结论:
- 基于贝拉塔塞普的救援方案显示了可比的结果.
- eGFR,移植存活率,感染/瘤率和DSA水平在不同疗法中是相似的.
- 支持贝拉塔塞普特在各种免疫抑制策略中的安全性和有效性.
相关概念视频
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
158
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
158
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
115
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
115
01:29Drugs for Treatment of Ulcerative Colitis in IBD
135
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
135
01:40Cell-mediated Immune Responses
68.1K
Overview
68.1K
01:29Inflammatory Bowel Disease IV: Pharmacological Management
126
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
126
01:27Tumor Immunotherapy
515
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
515